Li Ranran, Di Xiliang, Li Yuan, Li Hao, Liu Chonghua
Department of Oncology, The Linyi County People's Hospital, Dezhou, Shandong, China.
Department of Emergency, The Linyi County People's Hospital, Dezhou, Shandong, China.
Front Oncol. 2025 Feb 7;15:1531700. doi: 10.3389/fonc.2025.1531700. eCollection 2025.
Pulmonary sarcomatoid carcinoma (PSC) is a scarce pathologic type of lung cancer of non-small cell lung cancer (NSCLC) that exhibits resistance to conventional chemotherapy and radiotherapy, resulting in a poor prognosis. Herein, a 67-year-old man was admitted to the hospital in January 2022 with a diagnosis of PSC for over 6 months and a newly discovered brain metastasis for 4 days. He had previously undergone two unsuccessful chemotherapy regimens: bevacizumab combined with pemetrexed and loplatin, and albumin-bound paclitaxel combined with loplatin. Radiotherapy was performed for the brain and skull metastases, followed by treatment with tislelizumab combined with anlotinib, a programmed cell death protein 1 (PD-1) inhibitor with anti angiogenic drug, respectfully. The patient initially received nine cycles of treatment with tislelizumab and anlotinib, resulting in a significant shrinkage of the lung tumor. Subsequently, anlotinib was discontinued due to bleeding in the brain metastasis, and the patient received two additional cycles of tislelizumab. Following improvement in the hemorrhage from brain metastasis, the patient received two cycles of treatment with tislelizumab and anlotinib. Treatment was subsequently interrupted for 1 month due to the coronavirus disease 2019 (COVID-19) pandemic, which then resumed with two additional cycles of tislelizumab and anlotinib. Finally, the patient refused to continue treatment due to the progression of the brain metastasis and economic conditions, despite the stable condition. At this point, the patient has achieved over a year of progression-free survival, with overall survival exceeding 39 months. This case illustrates the efficacy and safety of combining antitumor immunotherapy with anlotinib, a targeted anti-angiogenic therapy.
肺肉瘤样癌（PSC）是一种非小细胞肺癌（NSCLC）中罕见的病理类型，对传统化疗和放疗具有抗性，预后较差。本文报告了一名67岁男性患者，于2022年1月入院，诊断为PSC已超过6个月，新发脑转移4天。他此前接受过两种化疗方案均未成功：贝伐单抗联合培美曲塞和洛铂，以及白蛋白结合型紫杉醇联合洛铂。对脑和颅骨转移灶进行了放射治疗，随后分别使用替雷利珠单抗联合抗血管生成药物安罗替尼进行治疗。患者最初接受了9个周期的替雷利珠单抗和安罗替尼治疗，肺部肿瘤显著缩小。随后，由于脑转移灶出血停用了安罗替尼，患者又接受了2个周期的替雷利珠单抗治疗。脑转移灶出血情况改善后，患者接受了2个周期的替雷利珠单抗和安罗替尼治疗。随后，由于2019冠状病毒病（COVID-19）大流行，治疗中断了1个月，之后恢复使用替雷利珠单抗和安罗替尼又进行了2个周期的治疗。最后，尽管病情稳定，但由于脑转移进展和经济状况，患者拒绝继续治疗。此时，患者已实现超过一年的无进展生存期，总生存期超过39个月。该病例说明了抗肿瘤免疫治疗与靶向抗血管生成治疗药物安罗替尼联合应用的疗效和安全性。
